CD200 and acute myeloid leukemia: The clinical utility of samalizumab, an anti-CD200 monoclonal antibody, is currently in being investigated in an open label phase Ib/II clinical trial to evaluate its therapeutic efficacy in newly diagnosed acute myeloid leukemia (NCT03013998).